{"cluster": 25, "subcluster": 2, "abstract_summ": "The criteria for the diagnosis of overt diabetes are either one fasting plasma glucose \u2265 126 mg/dL, or one random plasma glucose \u2265 200 mg/dL, or one glycated hemoglobin \u2265 6.5% When the screening procedure (OGTT) cannot be safely performed, the diagnosis of GDM is acceptable, if fasting plasma glucose is \u2265 92 mg/dL. In order to consider the impaired fasting glucose an acceptable surrogate for the diagnosis of GDM, the fasting glucose measurement should be performed within the recommended time windows for the risk level (high or medium risk).On-line resources for supporting women planning pregnancy as well as for self-management of pregnant women with type 1 diabetes (T1D) using intermittent or continuous glucose monitoring (CGM) are provided.CONCLUSIONS Research and audit activities will resume and we will find new ways for supporting pregnant women with diabetes to choose their preferred glucose monitoring and insulin delivery.In the absence of evidence for improvement of relevant endpoints, pharmacological therapies in pregnant women with early gestational diabetes at <24 + 0 weeks of gestation should be considered critically.BACKGROUND Pregnant women with diabetes are identified as being more vulnerable to the severe effects of COVID-19 and advised to stringently follow social distancing measures.", "title_summ": "Italian recommendations for the diagnosis of gestational diabetes during COVID-19 pandemic: Position statement AMD-SID, Diabetes and Pregnancy Study GroupDiabetes und Schwangerschaft \u2013 Update 2020Temporary changes in clinical guidelines of gestational diabetes screening and management during COVID-19 outbreak: A narrative reviewBreastfeeding and Medication Use in Kidney DiseaseManaging Diabetes in Pregnancy before, during and after COVID-19.Endocrinology in the time of COVID-19: Diagnosis and Management of Gestational Diabetes Mellitus.", "title_abstract_phrases": "On-line resources for supporting women planning pregnancy as well as for self-management of pregnant women with type 1 diabetes (T1D) using intermittent or continuous glucose monitoring (CGM) are provided.The criteria for the diagnosis of overt diabetes are either one fasting plasma glucose \u2265 126 mg/dL, or one random plasma glucose \u2265 200 mg/dL, or one glycated hemoglobin \u2265 6.5% When the screening procedure (OGTT) cannot be safely performed, the diagnosis of GDM is acceptable, if fasting plasma glucose is \u2265 92 mg/dL. In order to consider the impaired fasting glucose an acceptable surrogate for the diagnosis of GDM, the fasting glucose measurement should be performed within the recommended time windows for the risk level (high or medium risk).In the absence of evidence for improvement of relevant endpoints, pharmacological therapies in pregnant women with early gestational diabetes at <24 + 0 weeks of gestation should be considered critically.In women who have undergone bariatric-metabolic surgery, there are advantages for the mothers and increased risks for newborns, e.g., an increased rate of newborns small for gestational age after Roux-en\u2011Y gastric bypass.Temporary changes in clinical guidelines of gestational diabetes screening and management during COVID-19 outbreak: A narrative reviewBACKGROUND AND AIMS: New clinical approaches are needed to minimize complications of gestational diabetes during the COVID-19 outbreak with timely screening and proper management."}